Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ESRRB | O95718 | 6/20 | 0.41 |
| ▸ | ESRRA | P11474 | 6/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.40 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577530 | 0.83 | MAOA (0.49) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL802750 | 0.83 | MAOA (0.49) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL3195424 | 0.81 | ESR1 (0.48) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL8346705 | 0.79 | MAOB (0.46) | ALDH1A1MAPTRAB9AESR2MIF | |
| SCHEMBL26768863 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL14985710 | 0.77 | CYP2A6 (0.42) | MAPTCYP1A2ROCK2 | |
| SCHEMBL23111392 | 0.76 | ESRRB (0.40) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL26774785 | 0.76 | MAPK14 (0.41) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL26768871 | 0.76 | ESR1 (0.43) | ALDH1A1MAPTRAB9AESRRBESRRA | |
| SCHEMBL6122887 | 0.75 | ESRRB (0.45) | ALDH1A1MAPTRAB9AESRRBESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | claimed |
| EP-1718630-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | claimed |
| WO-2005082880-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS | WYETH (US) | 2005-09-09 | — | — | WO | claimed |
| US-7671084-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671084-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671084-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157492-B2 | Dibenzo chromene derivatives and their use as ERβ selective ligands | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1718630-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005082880-A1 | DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234074-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRB | ALDH1A1 2261/4885MAPT 4459/4885RAB9A 2460/4885 |
| US-20070049605-A1 | Dibenzo chromene derivatives and their use as ERbeta selective ligands | ESR2, ESR1, ESRRA | ALDH1A1 2552/4885MAPT 4472/4885RAB9A 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.